In this study, Neonc Technologies Holdings, Inc. showed that the cytotoxicity effects of its patented NEO212 compound Nasopharyngeal carcinoma (NPC) could inhibit NPC cell proliferation, and cause G2/M arrest and DNA damage. NEO212 is Neonc’s patented conjugated formulation of Temozolomide with Neonc’s highly purified Perillyl Alcohol. Temozolomide is a chemotherapy drug used primarily to treat […]